David Tai

机构：SingHealth, SingHealth Duke-NUS Academic Medical Centre, National University Cancer Institute, Singapore, Duke-NUS Medical School, National Cancer Centre Singapore · ORCID：0000-0002-2612-0065

发表论文 185 篇 · 总被引 4648 次 · h-index 30

代表论文

• Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 323)
• Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with pancreatic cancer (2025 · ESMO Open · 被引 11)
• 148O Overall evaluation of health-related quality of life (HRQoL) and efficacy assessment in patients (pts) who discontinued (d/c) due to treatment-related adverse events (TRAEs): Results from CheckMate 9DW (2025 · Annals of Oncology · 被引 4)
• Predicting recurrence patterns and outcomes following resection of pancreatic ductal adenocarcinoma: a contemporary real-world data cohort study (2026 · Annals of Medicine and Surgery · 被引 1)
• Using the EVendo Score to Predict Varices and Varices Needing Treatment in Hepatocellular Carcinoma Patients Planned for Atezolizumab-Bevacizumab (2026 · Digestive Diseases and Sciences · 被引 1)
• Neoadjuvant therapy versus upfront surgery for resectable pancreatic cancer: Updated systematic review, individual-patient-data meta-analysis and trial sequential analysis of randomized controlled trials (2025 · Surgery · 被引 1)